AbbVie Inc. (ABBV)
| Market Cap | 378.29B |
| Revenue (ttm) | 59.64B |
| Net Income (ttm) | 2.35B |
| Shares Out | 1.77B |
| EPS (ttm) | 1.32 |
| PE Ratio | 162.08 |
| Forward PE | 15.77 |
| Dividend | $6.92 (3.23%) |
| Ex-Dividend Date | Jan 16, 2026 |
| Volume | 8,107,472 |
| Open | 211.70 |
| Previous Close | 214.35 |
| Day's Range | 209.96 - 214.04 |
| 52-Week Range | 164.39 - 244.81 |
| Beta | 0.35 |
| Analysts | Buy |
| Price Target | 239.16 (+11.74%) |
| Earnings Date | Feb 4, 2026 |
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price target is $239.16, which is an increase of 11.74% from the latest price.
News
AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Based on the topline results from the EPCORE® DLBCL-1 trial, AbbVie along with partner Genmab will engage global regulatory authorities to discuss next steps NORTH CHICAGO, Ill., Jan. 16, 2026 /PRNews...
Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study
Danish drugmaker Genmab and its U.S. partner AbbVie said on Friday that their drug for a type of blood cancer failed to improve the survival rate in patients in a late-stage study.
AbbVie Inc. (ABBV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AbbVie Inc. (ABBV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AbbVie plans to build out its presence in obesity market
AbbVie said on Wednesday it is seeking to expand its presence in the fast-growing market for obesity treatments, leaning on the weight-loss drug it licensed last year from Danish biotech Gubra.
AbbVie reaches 3-year deal with White House to lower drug prices
CNBC's Andrew Ross Sorkin reports on the latest news.
AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.
The pharma company has agreed to cut some prices in exchange for an exemption from some levies.
AbbVie Strikes $100 Billion Investment Deal With Trump, Will Lower Medicaid Prices
As part of the three-year deal, the Trump administration exempted AbbVie from tariffs and future pricing mandates, the company said.
Abbvie, US reach agreement to cut drug prices
Abbvie reached a three-year agreement with U.S. President Donald Trump's administration to provide low prices in Medicaid through TrumpRx, and pledged $100 billion over the next decade for research an...
AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans
AbbVie will provide low prices in Medicaid, and expand affordable, direct-to-patient offerings for treatments used by millions of Americans through TrumpRx AbbVie will commit $100 billion in U.S. rese...
AbbVie, RemeGen partner on experimental solid tumor treatment
AbbVie said on Monday it would partner with RemeGen to develop an experimental treatment for solid tumors in a deal worth up to $4.95 billion, including milestones.
AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors
- RC148 is a novel PD-1/VEGF bispecific antibody being evaluated in multiple advanced solid tumors including certain lung cancers NORTH CHICAGO, Ill. and YANTAI, China, Jan. 12, 2026 /PRNewswire...
AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States
Milestone marks progress against AbbVie's previously announced commitment to invest more than $10 billion of capital in the U.S. over the next decade to broadly support innovation and expand critical ...
West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie
EXTON, Pa., Jan. 12, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that the company h...
MoneyShow's Best Investment Ideas For 2026: Part 1
MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, an...
AbbVie: The Dividend Does Not Lie
AbbVie Inc. maintains its Hold rating, as its latest dividend raise signals near-term earnings pressure and a decelerating growth trend. ABBV's Q1 2026 dividend increases 5.5% YOY, lagging both its pa...
AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling.
Shareholders in both drugmakers appear disappointed that a deal may not happen.
AbbVie in talks to buy biotech Revolution Medicines, WSJ reports
AbbVie is in advanced talks to buy cancer-drug developer Revolution Medicines , the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
AbbVie Near Deal for Revolution Medicines
AbbVie is in advanced talks to buy cancer-drug biotech Revolution Medicines, according to people familiar with the matter. Revolution Medicines has a market value of around $16 billion. It couldn't be...
AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call
NORTH CHICAGO, Ill., Jan. 7, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2025 financial results on Wednesday, February 4, 2026, before the market opens.
What Can Trigger A Breakout In Abbvie Stock?
AbbVie stock (NYSE:ABBV) has exhibited considerable rally potential, having once achieved over a 50% increase in less than two months in 2020. Furthermore, the stock has undergone seven rallies surpas...
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference
NORTH CHICAGO, Ill., Jan. 5, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present at the 44th Annual J.P.
AbbVie: Rocky Near-Term, Positive Long-Term
AbbVie outperformed the healthcare sector in 2025, but it remains to be seen whether the stock can repeat its performance in 2026. Last year, the stock was supported by relief for the pharmaceutical s...
My Most Important Warning To Dividend Investors For 2026
The U.S. government is increasingly funding deficits with short-term debt, making interest expenses highly sensitive to Fed policy. A declining average maturity in the sovereign bond index tightens th...